Mirum Pharmaceuticals, Inc. (MIRM)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Ask a question about Mirum Pharmaceuticals, Inc. (MIRM)
Company Performance

Current Price

as of Oct 16, 2024

$39.78

P/E Ratio

N/A

Market Cap

$1.9B

Description

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The firm focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its products include Maralixibat and Volixibat. The company was founded by Niall O'Donnel, Michael Grey and Christopher Peetz in May 2018 and is headquartered in Foster City, CA.

Metrics

Overview

  • HQFoster City, CA
  • SectorHealth Technology
  • IndustryPharmaceuticals: Major
  • TickerMIRM
  • Price$39.78+0.18%

Trading Information

  • Market Cap$1.90B
  • Float79.74%
  • Average Daily Volume (1m)361,832
  • Average Daily Volume (3m)467,878
  • EPS-$2.34

Company

  • Revenue$264.38M
  • Rev Growth (1yr)107.68%
  • Net Income-$24.64M
  • Gross Margin73.83%
  • EBITDA Margin-23.60%
  • EBITDA-$18.38M
  • EV$1.65B
  • EV/Revenue6.25
  • P/EN/A
  • P/S7.11
  • P/B8.26
Documents
SEC Filings
8-K (2024-08-07)
8-K (2024-06-17)
8-K (2024-06-06)
8-K (2024-05-31)
8-K (2024-05-08)
8-K (2024-02-28)
8-K (2024-01-16)
8-K (2024-01-08)
8-K (2023-12-18)
8-K (2023-11-02)
8-K (2023-10-17)
8-K (2023-10-13)
8-K (2023-09-11)
8-K (2023-09-05)
8-K (2023-08-30)
8-K (2023-08-03)
8-K (2023-07-17)
8-K (2023-06-13)
8-K (2023-05-04)
8-K (2023-04-17)
8-K (2023-04-12)
8-K (2023-04-06)
8-K (2023-03-10)
8-K (2023-03-08)
8-K (2023-01-09)
10-Q (2024-08-07)
10-Q (2024-05-08)
10-Q (2023-11-02)
10-Q (2023-08-07)
10-Q (2023-05-04)
10-K (2024-03-15)
10-K (2023-03-08)
Earnings Calls
Earnings Report 2024Q1
Earnings Report 2023Q4
Earnings Report (2023-11-05)
Earnings Report (2023-08-05)
Factset
Factset Business Description
Factset Street Account
StreetAccount Earnings Call Q&A Summary: Mirum Pharmaceuticals Q3 (2023-11-03T14:16:31Z)
Mirum Pharmaceuticals reports Q3 EPS ($0.57) vs FactSet ($0.61) [7 est, ($0.79)-(0.41)] ($28.39, 0.00) (2023-11-02T20:39:30Z)
Mirum Pharmaceuticals presents new data at The Liver Meeting ($30.04, +1.43) (2023-11-13T19:02:30Z)
Mirum Pharmaceuticals presents LIVMARLI data at NASPGHAN ($29.92, 0.00) (2023-10-07T23:47:30Z)
Mirum Pharmaceuticals initiated overweight at Morgan Stanley ($28.61, 0.00) (2023-11-13T10:52:24Z)
Mirum Pharmaceuticals EMBARK Phase 2B Study of LIVMARLI did not meet primary endpoint ($34.93, 0.00) (2023-12-18T13:34:02Z)
Mirum Pharmaceuticals announces phase 3 RESTORE study of Chenodal in cerebrotendinous xanthomatosis met its primary endpoint ($31.60, 0.00) (2023-10-02T12:35:13Z)
Mirum announces new PDUFA Date for LIVMARLI for the treatment of Cholestatic Pruritus in Progressive Familial Intrahepatic Cholestasis ($28.91, 0.00) (2023-10-17T20:31:22Z)